Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice close in Canuckland .70 up .09, but volume low.
This explains a lot.
Lexaria’s workgroup, including extensive ongoing R&D performed by Canada’s National Research Council on our behalf, continues to work closely with Altria to determine the appropriateness of the DehydraTECH technology for potential use in the global tobacco industry, via several product formats currently under investigation. Lexaria is making important, significant progress in its goal of achieving reduced-risk methods of nicotine delivery.
https://www.lexariabioscience.com/news/lexaria-bioscience-ceo-discusses-strategic-outlook/
67,000 bid @ .65 now!
Bids pilling up on Canadian side, 42,500 bid at .65
Ask now .70 in Great White North, only 1000 shares.
There is no category for drink powders it seems. Yes, Hill Street is supposed to make the powders in Canada, whether it will be branded as ChrgD+ I don't know.
Thanks, Brian Quigley,
'From Richmond, Virginia, Board Member of Lexaria & Advisor to The Boldt Runners Corporation, Brian Quigley said "This combination of superior science from Lexaria and a unique and strong branded proposition that Cannadips offers with its CBD pouch platform is a winning combination We are excited to be developing a category of products with best in class science to provide adult consumers the simple choice of a better product and a better alternative to tobacco and nicotine."
Altria's nomination to our BOD is already earning his keep!
https://www.lexariabioscience.com/news/lexarias-appoints-former-altria-group-senior-executive-and-operating-company-chief-to-board-of-directors/
I'm immediately selling everything and buying back at .14. Thank you for your ongoing technical analysis all4.
Surging volume says you're wrong.
OK thanks, we got it the first time!
What do we need for a share price to attain Chris' dream of listing on the big board in the US?
Today the biggest volume day since February!
Summary
2019 was the best year of corporate progress that Lexaria has ever experienced. We started the year with a major announcement with one of the world’s largest companies evaluating our technology, including a negotiated royalty fee applicable to world-wide sales of products utilizing DehydraTECH: our biggest licensing deal ever. We hope to announce ongoing progress with this relationship early in 2020, and we also hope to attract new Fortune 500 CPG licensees in the coming year as well.
Through a partner, we opened a new US facility capable of manufacturing at a potential current rate of up to 200,000 servings of enhanced DehydraTECH powders per day, and we expect this to begin generating licensing as well as fee-for-goods and services revenues for us in early 2020. We signed new corporate clients in the cannabinoid sector throughout the year, many of whom expect to commence retail operations in 2020, and we are increasingly attracting the interest of larger, more established MSOs in the field.
We received approval from Health Canada to open and operate our new cannabis R&D facility in our head office newly-built in Kelowna, Canada, through which we intend to continue to broaden our formulation and IP development and increasingly attract Canadian DehydraTECH licensees with the recent dawn of the legal edibles sector in Canada.
We received our first medical claim patent grants, opening the door to increased likelihood of pharmaceutical operations to come. Lexaria continues to develop its proprietary drug delivery platform and is working on commercial release of DehydraTECH version 2.0 sometime in 2020 with even faster delivery than ever before.
We continue to face headwinds that we need to overcome. We need to evidence wider adoption of our technology within the cannabinoid industries. We also need to provide evidence to the investing public that Lexaria is not a cannabis production company but instead should be distinguished and valued as a leading biotech company with a patented, proprietary drug delivery technology with applications to many industries.
Lexaria expects strong, sustainable revenue growth in 2020 and beyond. We are working towards an application for a national stock exchange listing; hoping to announce additional Fortune-500 relationships; and significant new client relationships.
We are working diligently so that, when we look back on 2020 we remember it only as, “It was the best of times…”
Of course, Lexaria has been working with Canada's National Research Council on DehydraTECH since Feb. 2017.
https://www.lexariabioscience.com/news/lexaria-bioscience-completes-initial-project-with-canadas-national-research-council/
This and the fact that Altria nominated Brian Quigley to Lexaria's BOD help keep me invested.
https://www.lexariabioscience.com/news/lexarias-appoints-former-altria-group-senior-executive-and-operating-company-chief-to-board-of-directors/
I like that Canada National Research Council + Lexaria + Altria = ?
"Lexaria’s workgroup, including extensive ongoing R&D performed by Canada’s National Research Council on our behalf, continues to work closely with Altria to determine appropriateness of the DehydraTECH technology for potential use in the global tobacco industry, via several product formats currently under investigation. Lexaria is making important, significant progress in its goal of achieving reduced-risk methods of nicotine delivery."
Nothing about what they did to increase shareholders' values? LOL
Remember Lexaria's laboratory is licensed and inspected by Health Canada.
https://www.lexariabioscience.com/news/lexaria-bioscience-receives-cannabis-rd-license-from-health-canada/
0 Shares traded in The Great White North!
My God! That lunchroom is just stunning! I'm going all-in now. LOL
This tech. has been around for a while it was first patented in 2015 and studies were conducted prior, I can't find any reference to it being used with any other substance than curcumin, so I doubt if it's a real competitor to us.
https://vs-corp.com/longvida-optimized-curcumin-receives-us-patent-9192644/
Their Curcumin compound does have some real health benefits though: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518252/
The tech. seems like it might be competitive.
Another CBD powder. This one is made with an isolate and they seem to have a problem with bitterness.
https://www.foodnavigator-usa.com/Article/2019/12/12/Caliper-CBD-CEO-Cut-off-between-drugs-and-food-for-CBD-should-be-around-dosage-not-isolate-vs-extract?fbclid=IwAR1GRS-XVQYZIwLgA3vSgZZRf2TcXXnmQfeb55J8WuoQhlLkpuugvaR-KXg
Yeah really, ChrgD+ plus only launched 3 months ago and he wants to know why there hasn't been a surge in sales? They haven't even had time to tally one quarter of sales yet.
Hill Street Reports FQ1 2020 Results
Toronto, Ontario--(Newsfile Corp. - November 28, 2019) - Hill Street Beverage Company Inc. (TSXV: BEER) ("Hill Street" or "the Company") reported its fiscal Q1 2020 financial results for the three-month period ended September 30, 2019. A complete set of financial statements and Management's Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
FQ1 2020 Financial Highlights
• Distributor Sell-In to Retail customers was +5% vs same period year ago.
• Gross Margin on Revenues of $514K improved from 27% to 35% vs same period year ago due to product mix and positive foreign exchange.
• Net loss of $1.5M compared to a net loss of $1.2M in FQ1 2018 driven by several one-time expenses associated with entering the cannabis vertical.
• End of quarter cash position of $204K, no debt, and positive working capital of $0.6M.
"Hill Street has made major strides in building both our brand and distribution for our alcohol-free products over the past two years, and the increase in sell-through to retail is an excellent indicator of our progress. The company has continued to move forward with our plans to enter the Cannabis 2.0 market in spite of the headwinds of the capital markets, major missteps made by billion-dollar cannabis companies, and the overall downturn in the sector, with excellent preparation and analysis for the launch of infused cannabis beverages in 2020," said Terry Donnelly, Hill Street Beverage Co.'s Chairman & CEO. "Our team has taken these challenges in stride, and continues to punch above their weight, with excellent response from retailers for our holiday gift pack and trade promotion for the coming season."
Results of FQ3 2019 Operations
Results for the Period Ended Quarter Ended
September 30, 2019 Quarter Ended
September 30, 2018
Gross Revenue $ 513,766 $ 793,867
Chargebacks, finance fees, and listing fees $ 184,327 $ 282,260
Net Revenue $ 329,439 $ 511,607
Direct Costs $ 152,036 $ 294,613
Gross profit $ 177,403 $ 216,994
Operating Expenses $ 1,002,158 $ 886,829
Other One-time Expenses $ 545,850 $ 304,675
Non Cash Expenses $ 154,982 $ 221,286
Loss before other Income (Expense) $ 1,525,587 $ 1,195,796
Other income (Expenses)
Charges related to RTO $ 0 $ 918,345
Fo reign exchange gain (loss) $ 12,324 $ (14,888 )
Write-off of inventory $ 0 $ (8,007 )
Write-off of intangibles $ 8,000 $ 0
Other Income $ 0 $ 2,640
Loss and comprehensive loss for the period $ 1,545,911 $ 2,134,396
Basic and diluted loss per common share $ 0.02 $ 0.03
Weighted average number of common shares outstanding 96,845,070 64,157,068
Q1 F2020 Operational Highlights
• Hill Street's planned acquisition of OneLeaf Cannabis was mutually terminated on September 30, 2019. Acquisition cost, higher than expected capital expenditures to bring the facility online and lack of clarity from Health Canada concerning the timing of One Leaf's licence grant contributed to the mutual decision.
• Hill Street continued to be active in both Industry and Capital markets investor events:
o Keynote speaker at the inaugural Cannabis Drinks Expo in San Francisco;
o Presented at the Micro Cap Investor conference in NYC, which focused on cannabis edibles;
o Keynote at McGill Centre for Cannabis Research;
o Presented at Extraordinary Futures Conference in Vancouver;
o Presented at the Thinking Capital Conference in Toronto;
o Presenting Sponsor at O'Cannabiz in Niagara Falls.
• Alcohol-free Holiday commitments to the promotional "Entertainers Pack" increased 300% versus same period year ago.
• Fortinos, a large format Retailer with 23 stores in Southern Ontario owned by Loblaws Companies Limited, agreed to list all seven (7) stock-keeping-units ("SKU's") of Hill Street's Vin(Zero) wine and Craft beer. The on-shelf date is October 2019, in time for the important holiday period.
• Five (5) Hill Street SKU's are now available for immediate orders on Amazon.ca.
"I'm delighted to see more retail accounts in more regions embrace the promotion. This beautiful designed mix-pack of red, white and sparkling brut is the perfect compliment for entertaining this holiday season," said Doug Taylor, Chief Commercial Officer.
Highlights Subsequent to September 30, 2019
• Hill Street has begun negotiations with several co-packing partners across Canada to produce its cannabis-infused products, including its award-winning alcohol-free wine and beer. On November 12, 2019, the company announced its first co-packing agreement with Peak Processing Solutions of Windsor, Ontario. Additional co-packing agreements are expected to be announced in due course.
For further information:
Press only:
Terry Donnelly, Chairman, and CEO, Hill Street Beverage Company Inc.,
terry@hillstreetbevco.com, (416) 543-4904;
Investors:
Sean Peasgood, Investor Relations,
sean@sophiccapital.com, (647) 797-0219
About Hill Street Beverage Company Inc. (TSXV: BEER)
Hill Street Beverage Company is the world's most award-winning company exclusively focused on alcohol-free beer, wine, and adult format beverages. Hill Street's great-tasting alcohol free products include Hill Street Craft Brewed Lager, Designated Draf t Pilsner beer, Vin(Zero) and Vintense wines. All have won numerous medals and accolades including three Gold, two Silver, and two Bronze Medals at the U.S. Open Beer Championships, the Retail Council of Canada's Grand Prix award, and a prestigious Double Gold Medal at the San Francisco International Wine Challenge. Hill Street will also produce and sell cannabis-infused adult beverages shortly after edibles becomes legal in Canada, expected to occur on October 17, 2019. Check out Hill Street's award-winning line-up and order product to be delivered straight to your home at www.hillstreetbeverages.com.
I'm jealous. I can't order from the Canadian company that I'm invested in because I'm Canadian and it doesn't look like it will be available in Canada anytime soon, as far as I know, Lexaria has not yet applied to Health Canada for a permit to sell either one of these products here and it takes at least 60 days to get a permit.
Lexaria closes $699,410 (U.S.) tranche of placement
2019-11-14 07:26 ET - News Release
Mr. Alex Blanchard reports
LEXARIA ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT
Lexaria Bioscience Corp. has closed the first tranche of its previously announced private placement of units as at Nov. 13, 2019.
Pursuant to the company's news release of Oct. 30, 2019, the company announces that it has closed this tranche of its offering and has received gross proceeds of $699,410.25 (U.S.) from the sale of an aggregate 1,554,245 units at a price of 45 U.S. cents per unit. Each unit comprises one common share and one share purchase warrant whereby the holder of a warrant will be entitled to exercise the warrant to purchase an additional share at a price of 80 U.S. cents until Nov. 13, 2020, and thereafter at a price of $1.20 (U.S.) until Nov. 13, 2021. The warrants will expire and will no longer be exercisable after the expiry date.
The company also paid $3,937.50 (U.S.) and issued 8,750 warrants to certain finders in connection with the investment by investors of an aggregate 125,000 units. The broker warrants have the same exercise terms and expiry date as the warrants.
The net proceeds received from the offering will be used as to $200,000 (U.S.) for continued research and development of the issuer's DehydraTECH technology; $50,000 (U.S.) for sales and marketing of the issuer's products; $50,000 (U.S.) for finance and legal fees; $75,000 (U.S.) for pursuing patent applications; $170,000 (U.S.) for general working capital; and $150,000 (U.S.) for administration costs.
About Lexaria Bioscience Corp.
Lexaria Bioscience is a global innovator in drug delivery platforms. Its patented DehydraTECH drug delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules.
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.
Yes, great IP and also don't forget the extensive safety testing.
https://www.lexariabioscience.com/news/lexaria-bioscience-completes-initial-project-with-canadas-national-research-council/
Expect to hear from this lady soon...
https://www.cowen.com/profile/vivien-azer/
Ho, Hum and yawn, the market doesn't care!
"Cowen cannabis and alcoholic beverage analyst Viven Azer said the U.S. market for cannabis drinks is small, fragmented, and without a clear leader. That’s the case, she said, because early products in states where cannabis sales are legal get people stoned for a long time, and lack consistent intensity, onset, and offset for the high users feel. They’re also expensive, she added."
https://ca.finance.yahoo.com/news/pot-drinks-for-newbies-canopy-growth-strategy-172628533.html?soc_src=social-sh&soc_trk=tw
I agree with you about the competition aspect. My thoughts are that what's probably holding up the advancement of the nicotine product is Shelf Stability testing. Altria doesn't want to market a product that may break down after a short period of time. They have to be able to put a best before date on their product and be confident that it will be stable until after that date. This testing, of course, takes time.
Sounds legit to me Abundance, Hill Street is just about out of cash they need financing, but I don't think Lexaria would be participating in that financing when they need cash to keep their own lights on.
I think something is up though, and I believe they may have something to announce in the morning. Like I said very unusual to announce a dilutive financing mid-week. Fingers are crossed. JMHO
Why the heck didn't Lexaria ask it's existing shareholders to participate in their financing?
This financing must have been negotiated about 3 weeks ago when the issue price would have been at a slight discount to the market price, not the 25% it is now.
I find the timing of this financing announcement a bit strange, these dilutive financings are almost always announced on a Friday to reduce the impact on the share price.
So why announce this on Wednesday, are they clearing the decks for another announcement this week?